歐普康視(300595.SZ):目前有塑形鏡、阿托品院內製劑、減離焦框架鏡等近視防控產品
格隆匯5月17日丨有投資者在投資者互動平台向歐普康視(300595.SZ)提問,“現在治療近視的眼科藥物上市,是否對公司產生不利影響。公司是否有類似的藥物研發。公司的產品與治療近視的藥物相比有哪些優勢。”
歐普康視回覆稱,專家鼓勵阿托品與塑形鏡聯合使用防控近視。公司有阿托品院內製劑已在臨牀應用。公司目前有塑形鏡、阿托品院內製劑、減離焦框架鏡等近視防控產品,還有一些產品在研。主營產品角膜塑形鏡的突出優勢有:(1)可以立即讓用户白天不戴眼鏡;(2)近視控制效果已經過18年、超過200萬的用户證明是普遍有效的。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.